Literature DB >> 23199321

Suppression, subversion and escape: the role of regulatory T cells in cancer progression.

K Oleinika1, R J Nibbs, G J Graham, A R Fraser.   

Abstract

Regulatory T cells (T(regs) ) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self- and tumour-associated antigens, T(regs) are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti-tumour responses. Suppression mechanisms employed by T(regs) are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti-tumour responses. This review will focus on the current evidence supporting the central role of T(regs) in establishing tumour-specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of T(regs) accumulation within the tumour, including enhanced recruitment, in-situ or local proliferation, and de-novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of T(regs) . The role of T(regs) is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23199321      PMCID: PMC3530093          DOI: 10.1111/j.1365-2249.2012.04657.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  106 in total

1.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Authors:  E D Kwon; B A Foster; A A Hurwitz; C Madias; J P Allison; N M Greenberg; M B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

3.  TCR v(beta) usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture.

Authors:  R A Kurt; J A Park; S F Schluter; J J Marchalonis; E T Akporiaye
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

4.  Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.

Authors:  Jun Shimizu; Sayuri Yamazaki; Takeshi Takahashi; Yasumasa Ishida; Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

5.  Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo.

Authors:  S Radoja; T D Rao; D Hillman; A B Frey
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

6.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

Authors:  A A Hurwitz; B A Foster; E D Kwon; T Truong; E M Choi; N M Greenberg; M B Burg; J P Allison
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

Review 7.  Targeting regulatory T cells.

Authors:  Christine Ménétrier-Caux; Tyler Curiel; Julien Faget; Manuarii Manuel; Christophe Caux; Weiping Zou
Journal:  Target Oncol       Date:  2012-02-12       Impact factor: 4.493

8.  Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer.

Authors:  Gareth Betts; Emma Jones; Syed Junaid; Tariq El-Shanawany; Martin Scurr; Paul Mizen; Mayur Kumar; Sion Jones; Brian Rees; Geraint Williams; Awen Gallimore; Andrew Godkin
Journal:  Gut       Date:  2011-12-29       Impact factor: 23.059

9.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors:  R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.

Authors:  A Iellem; M Mariani; R Lang; H Recalde; P Panina-Bordignon; F Sinigaglia; D D'Ambrosio
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

View more
  73 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 2.  Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?

Authors:  Elisa Gobbini; Matteo Giaj Levra
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.

Authors:  Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig-Fariñas; Ana Blasco; Eva García Del Olmo; Ricardo Guijarro; Miguel Martorell; Carlos Camps; Rafael Sirera
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

4.  ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.

Authors:  Huanling Zhang; Yanyan Li; Xiaoping Liu; Zhaoduan Liang; Mengyong Yan; Qiang Liu; Anan Chen; Yifeng Bao; Chengzhi Zhou; Shiyue Li; Cassian Yee; Yi Li
Journal:  Immunology       Date:  2018-06-14       Impact factor: 7.397

5.  p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.

Authors:  Nicola R Hardwick; Mary Carroll; Teodora Kaltcheva; Dajun Qian; Dean Lim; Lucille Leong; Peiguo Chu; Joseph Kim; Joseph Chao; Marwan Fakih; Yun Yen; Jonathan Espenschied; Joshua D I Ellenhorn; Don J Diamond; Vincent Chung
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

6.  IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.

Authors:  Qingshan Li; Xin Xu; Weijie Zhong; Qinghua Du; Bizhen Yu; Huabao Xiong
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

7.  Frontiers in Intravital Multiphoton Microscopy of Cancer.

Authors:  Louisiane Perrin; Battuya Bayarmagnai; Bojana Gligorijevic
Journal:  Cancer Rep (Hoboken)       Date:  2019-06-20

Review 8.  Novel Immunotherapy Combinations.

Authors:  Babar Bashir; Melissa A Wilson
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

9.  MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Authors:  Eleftheria A Anastasopoulou; Ioannis F Voutsas; Michael Papamichail; Constantin N Baxevanis; Sonia A Perez
Journal:  Oncoimmunology       Date:  2016-05-02       Impact factor: 8.110

Review 10.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.